Differences Between Highly Purified and Non-Highly Purified Human Menopausal Gonadotropin
The primary difference between highly purified and non-highly purified human menopausal gonadotropin (hMG) lies in their specific activity and protein contaminant levels: highly purified hMG has a specific activity of at least 10,000 IU/mg with minimal contaminants, while non-highly purified preparations have specific activity between 4,000-5,000 IU/mg with significantly higher levels of urine-derived protein contaminants.
Understanding the Purification Difference
The purification process directly impacts product quality 1:
- Highly purified hMG (hp-hMG): Contains ≥10,000 IU/mg specific activity with lower levels of contaminant proteins from urine extraction
- Non-highly purified hMG: Contains 4,000-5,000 IU/mg specific activity with substantial urine-derived protein contaminants including oxidized FSH
Both preparations are extracted from postmenopausal women's urine and contain both FSH and LH activity, but the degree of purification affects the ratio of active hormone to total protein content 1.
FSH-Only vs. hMG: The Potency Question
FSH derived from menopausal women (urinary FSH) is NOT equivalent in potency to hMG that contains both LH and FSH—the presence of LH activity in hMG provides critical synergistic effects that pure FSH preparations cannot replicate, particularly in specific patient populations.
Clinical Evidence for LH Requirement
The most compelling evidence comes from patients with hypogonadotropic hypogonadism, where the difference is stark 2:
- hMG treatment resulted in significantly better outcomes: more leading follicles, higher serum estradiol levels, greater endometrial thickness, and higher ovulation rates
- Pure FSH treatment required significantly more ampules but produced inferior results across all parameters
- This supports the two-cell two-gonadotropin hypothesis: both FSH and LH are required for appropriate steroidogenesis 2
Context-Dependent Equivalence
However, the clinical context matters significantly:
When GnRH agonist suppression is used (as in standard IVF protocols), the difference between hMG and FSH largely disappears 3. In these downregulated patients, no significant differences were found in:
- Day of hCG administration
- Peak estradiol levels
- Number of oocytes retrieved
- Embryo transfer rates
- Pregnancy rates
The key distinction: When endogenous LH is suppressed by GnRH agonists, exogenous LH activity becomes less critical because the pituitary-ovarian feedback is already disrupted 4.
Functional Hypothalamic Amenorrhea Context
In women with functional hypothalamic amenorrhea requiring fertility treatment, the guideline explicitly notes that women may require both LH and FSH activity for optimal gonadotropin response 4. The evidence showed inadequate estradiol responses in women treated with recombinant FSH without LH activity, suggesting LH activity is essential in individuals without endogenous LH 4.
Clinical Implications for Practice
When to Choose hp-hMG:
- Patients with hypogonadotropic hypogonadism (where endogenous LH is absent)
- Functional hypothalamic amenorrhea patients requiring fertility treatment
- When physiologic hormone ratios are desired
- Patients who may benefit from LH activity for steroidogenesis
When FSH Alone May Suffice:
- Standard IVF protocols with GnRH agonist downregulation
- Patients with adequate endogenous LH levels (0.5-1.5 IU/L during midfollicular phase) 5
- When minimizing risk of ovarian hyperstimulation syndrome (OHSS)
Important Caveats:
Adding exogenous LH when not needed can be problematic 5. In normogonadotropic patients with serum LH 0.5-1.5 IU/L during long GnRH-agonist protocol, hMG supplementation resulted in:
- Higher estradiol levels but lower fertilization rates (69.6% vs 89.1%)
- Increased risk of OHSS
- No improvement in pregnancy rates
Recent comparative studies show mixed results depending on patient population 6, 7, 8, with some showing advantages for rFSH in terms of oocyte numbers in certain populations, while others show equivalence in pregnancy outcomes, reinforcing that patient selection and protocol type are critical determinants.
Product Quality Considerations
When selecting between preparations, highly purified products (specific activity ≥10,000 IU/mg) are preferable to minimize exposure to protein contaminants and oxidized FSH, which have no therapeutic benefit and may contribute to adverse reactions 1, 9.